Antiviral compounds
OwnerRichard A. Partis, Francis J. Koszyk +1inventors
InventorsRichard A. Partis, Francis J. Koszyk, Richard A. Mueller
Life of this patent
Estimating the term…
Loading patent…
OwnerRichard A. Partis, Francis J. Koszyk +1inventors
InventorsRichard A. Partis, Francis J. Koszyk, Richard A. Mueller
Estimating the term…
A method of inhibiting lentivirus is disclosed which comprises mammalian host susceptible to said lentivirus with a virally inhibitory effective amount of an O-acylated derivative of 1,5-dideoxy-1,5-imino-D-glucitol and their N-alkyl, N-acyl and N-aroyl derivatives in which from one to four of the free hydroxyl groups are O-acylated with carboxylic alkanoyl radicals selected from the group consisting of .omega.,.omega.,.omega.-trifluoroalkanoyl having from three to eight carbon atoms, carboxylic cycloalkanoyl groups having from four to eight carbon atoms and carboxylic acyclic alkanoyl groups having from two to ten carbon atoms, wherein the N-aroyl groups contain from 7 to 14 carbon atoms, the N-acyl groups contain from 4 to 8 carbon atoms and the N-alkyl groups contain from 1 to 14 carbon atoms.
The method of inhibiting lentivirus by orally administering to a mammalian host susceptible to said lentivirus a virally inhibitory effective amount of 1,5-dideoxy-1,5-[3-(4-chlorophenoxy)-1-oxopropyl]-imino]-D-glucitol, tetraacetate.
The method of inhibiting lentivirus by orally administering to a mammalian host susceptible to said lentivirus a virally inhibitory effective amount of 1,5-(butylimino)-1,5-dideoxy-D-glucitol, 2,4,6-tri-(2,2-dimethylpropanoate).
Dependencies are inferred from the claim text.